Introduction {#s1}
============

Over the past decade, *Nicotiana benthamiana* expression systems using viral and non-viral vectors have become viable platforms for the production of recombinant proteins (Matoba et al., [@B38]; Whaley et al., [@B65]; Chen et al., [@B6]; Nandi et al., [@B44]). Taking advantage of the systems\' capacity to rapidly express complex proteins within days, a number of novel biopharmaceutical proteins, including monoclonal antibodies and subunit vaccine antigens, have been produced in *N. benthamiana* and showed protective efficacy in preclinical animal challenge models (Santi et al., [@B50]; Massa et al., [@B37]; Mett et al., [@B43], [@B42]; D\'aoust et al., [@B8]; Lai et al., [@B27], [@B28]; Landry et al., [@B30]; Wycoff et al., [@B68]; Karauzum et al., [@B22]; Chichester et al., [@B7]; Petukhova et al., [@B46]; Shoji et al., [@B54]; Garcia et al., [@B15]; Hiatt et al., [@B20]; Qiu et al., [@B48]; Mardanova et al., [@B34]; Pillet et al., [@B47]; Tsekoa et al., [@B59]). Medicago Inc. has recently obtained a U.S. Food and Drug Administration\'s emergency use authorization for *N. benthamiana*-expressed hemagglutinin-based virus-like particle vaccine for H5N1 influenza virus, and will soon initiate a multi-center Phase III clinical trial for a quadrivalent seasonal influenza vaccine, highlighting the regulatory and commercial feasibility of the plant expression technology for biopharmaceuticals development (<http://medicago.com>).

Subunit vaccines are composed of non-replicating/pathogenic microbial components containing critical epitopes and are therefore considerably safer than live-attenuated vaccines, but their inherently weak immunogenicity often poses challenges for sufficient vaccine efficacy (Schiller and Lowy, [@B51]; Vartak and Sucheck, [@B62]). One of the effective approaches to improve vaccine efficacy is targeting antigens to pattern recognition receptors on dendritic cells (DCs), macrophages and other antigen presenting cells (Kumar et al., [@B24]; Takeuchi and Akira, [@B57]). Among others, antigen mannosylation has been proposed as a promising strategy because it increases antigen uptake by mannose-specific C-type lectin receptors such as DC-specific intracellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) and mannose receptor (Lam et al., [@B29]; Al-Barwani et al., [@B1]; Sedaghat et al., [@B53]). Upon binding to C-type lectin receptors, glycosylated antigens are internalized and subsequently targeted for antigen delivery and stimulation of T cell responses (Apostolopoulos et al., [@B2]; Van Kooyk et al., [@B60]). Thus, development of an efficient recombinant production platform for mannosylated glycoprotein antigens may facilitate vaccine development. Especially, Man~9~GlcNAc~2~, a high-mannose-type glycan (HMG) with 9 mannosyl residues (Man9) has a higher binding affinity to DC-SIGN than other HMGs with fewer mannoses (Man5-8) and complex-type *N*-glycans (Feinberg et al., [@B14], [@B13]; Van Liempt et al., [@B61]). Therefore, our ultimate goal is the production of Man9-rich glycoprotein vaccine antigens in plants.

Mannose trimming reactions from the precursor Glc~3~Man~9~GlcNAc~2~ occur in the early stages of the *N*-glycan processing pathway following the removal of terminal Glc residues, in which endoplasmic reticulum (ER)-type and Golgi α-mannosidase-I proteins are responsible for the initial step of mannose trimming (Liebminger et al., [@B31]; Strasser, [@B56]). Here, we attempted to establish an optimal kifunensine-treatment procedure in a hydroponic culture of *N. benthamiana* to obtain highly mannosylated, Man9-displaying recombinant vaccine antigens. Kifunensine is an α-mannosidase I inhibitor, which has been used in mammalian cell culture systems to modify the *N*-glycan profile of glycoproteins to be rich in Man9 HMGs (Elbein et al., [@B12]). However, its application and optimal conditions in whole-plant transient overexpression systems have not been reported. We used cholera toxin B subunit (CTB) and the envelope glycoprotein gp120 of human immunodeficiency virus type-1 (HIV-1), both containing a C-terminal H/KDEL ER retention signal, as model antigens in the present study. H/KDEL-tagged proteins were used in this study because, although the ER-retention strategy has been frequently used to produce recombinant proteins in plants, the signal usually brings about predominantly Man6-8 glycoforms and is sometimes leaky, resulting in heterologous glycan compositions with few Man9 glycans (Petruccelli et al., [@B45]; Matoba et al., [@B39]; Gomord et al., [@B16]; Loos et al., [@B33]; Triguero et al., [@B58]; Wang et al., [@B63]; Hamorsky et al., [@B19]). CTB is a potent mucosal immunogen used in the internationally licensed cholera vaccine Dukoral®. We have recently shown that CTB is *N*-glycosylated when expressed in *N. benthamiana* (Hamorsky et al., [@B18], [@B19]). The *N*-glycosylated CTB (gCTB) bound to cell-surface DC-SIGN in addition to GM1-ganglioside receptors, indicating that the glycosylated vaccine antigen may elicit additional immunomodulatory activity via several C-type lectin receptors (Matoba, [@B40]). Furthermore, preliminary results showed that gCTB\'s DC-SIGN-binding affinity could be significantly enhanced when the protein was produced under kifunensine treatment (Hamorsky et al., [@B19]), providing a basis for the present study and for the development of novel C-type lectin receptor-targeting vaccines. HIV-1 gp120, on the other hand, is a primary target of broadly neutralizing antibodies, thus constituting an important component of experimental HIV-1 vaccines (Zhou et al., [@B69]; Karlsson Hedestam et al., [@B23]; McElrath, [@B41]). Our results in the present work demonstrate that recombinant glycoproteins transiently expressed in *N. benthamiana* have predominantly Man9 HMGs upon hydroponically treating the plant with kifunensine after vector inoculation, providing a new method for the efficient production of highly mannosylated antigens for vaccine development.

Materials and methods {#s2}
=====================

Vector construction, expression, and purification of gCTB and gp120 in *N. benthamiana*
---------------------------------------------------------------------------------------

Proteins were transiently overexpressed using the magnICON® deconstructed tobamovirus vector (pICH11599, ICON Genetics, Halle/Saale, Germany; Marillonnet et al., [@B35]). Vector construction and purification of gCTB, which contains a C-terminal KDEL sequence, were described previously (Hamorsky et al., [@B19]). The gp120 construct used in this study was derived from an *env* clone of the CCR5-using clade C virus DU156 (Genbank No. [DQ411852](DQ411852)). See Supplemental Methods for vector construction, expression, and purification of gp120. The purified protein was analyzed via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) whereas its concentration was measured by the bicinchoninic acid (BCA) protein assay using HEK293 cell-produced gp120~DU156~ (Immune Technology Corp, New York, NY) as a reference control.

Kifunensine, ascorbic acids treatments of hydroponically grown *N. benthamiana* for transient protein expression
----------------------------------------------------------------------------------------------------------------

Following agroinfiltration, 12 plants were removed from soil and transferred to hydroponic cultures for varying kifunensine (kif) treatments (Cayman Chemical, Ann Arbor, MI) with each group containing 3 plants, viz., control receiving no kif at all (0 kif), plants receiving kif only once (1 kif), twice (2 kif) and/or thrice (3 kif) during post inoculation growth (Figure [1](#F1){ref-type="fig"}). Protein extraction and purification was carried out at 5 days post inoculation (dpi) as described below. For ascorbic acids treatment, nine plants were used. Under the 3 kif conditions, a final concentration of 0.3 mM of [l]{.smallcaps}-ascorbic acids, adjusted to pH 5.8, was added to the hydroponic culture. RNA extraction and protein purification were performed at 2 and 5 dpi, respectively.

![Study design and conditions. **(A)** A flow chart for agroinfiltration and hydroponic kifunensine treatment of *N. benthamiana*. **(B)** Kifunensine treatment conditions. The α-mannosidase I inhibitor was added at different time intervals; at the time of hydroponic setup (Day 0), and then added every other day, i.e., Day 2 and then Day 4 at the dose indicated.](fpls-09-00062-g0001){#F1}

RNA extraction, reverse transcription, RT-qPCR
----------------------------------------------

Total RNA was extracted from 100 mg of fresh plant leaf material (*n* = 9). Plant tissues were lysed by grinding the tissue using liquid nitrogen and with a mortar and pestle. The samples were prepared by QIAShredder (Qiagen) and RNAqueous Phenol-free total RNA Isolation Kits (Thermo Fisher Scientific, Waltham, MA), following manufacturer\'s protocol. After total RNA isolation, TURBO DNA free kit (Thermo Fisher Scientific) was used to eliminate genomic DNA. For reverse transcription, first strand cDNA (2 μg) was synthesized using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). RT-qPCR was performed on an StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific) with SYBR Green PCR master mix (Thermo Fisher Scientific). The primers for *BiP, PDI*, and *bZIP60* and RT-qPCR conditions were followed as described previously (Hamorsky et al., [@B19]).

Biochemical analysis of gCTB glycans
------------------------------------

Endoglycosidase H (Endo H) and peptide-*N*-glycosidase F (PNGase F) digestions were performed as described previously (Matoba et al., [@B39]). Briefly, CTB proteins (2 μg) were incubated with Endo H or PNGase F (2000 units each) overnight at 37°C, separated by SDS-PAGE, transferred to a PVDF membrane, and probed with anti-CTB antibodies. Band intensities were measured using Carestream MI SE software. Data was expressed as a percentage of the proportion of glycosylated band remaining after each enzymatic digestion compared to untreated glycosylated band for a given kifunensine treatment. For plant-specific glycan detection, rabbit anti-xylose and anti-fucose antibodies (Agrisera, Vännäs, Sweden; 0.1 μg/mL and 0.05 μg/mL, respectively) were used as probes to detect gCTB in immunoblot analysis.

Quantification of gCTB in *N. benthamiana* leaf extract
-------------------------------------------------------

GM1-ganglioside-capture enzyme-linked immunosorbent assay (GM1-ELISA) was used for the detection and quantification of gCTB using a commercial CTB (List Biological Laboratories, Campbell, CA), as described previously (Matoba et al., [@B39]; Hamorsky et al., [@B18]).

High performance liquid chromatography-mass spectrometry analysis of gp120 *N*-glycans
--------------------------------------------------------------------------------------

Glycan profiling was performed as previously described (Matoba et al., [@B39]; Hamorsky et al., [@B18]). For reference, recombinant gp120 produced in HEK cells (DU156.12, Clade C (Immunetech \# It-001-RC1p) was used. Briefly, glycans were released from gp120 by hydrazinolysis, which were pyridylaminated and separated by reversed phase high-performance liquid chromatography (RP-HPLC) and size-fractionation (SF)-HPLC. The glycan structures were determined by RP-HPLC and tandem mass spectrometry (MS/MS), with their retention times and MS/MS profiles compared with those of an in-house MS/MS library constructed using commercial 2-aminopyridine (PA)-labeled standards of known isomeric configurations.

Statistical analyses
--------------------

Statistical significance was analyzed by one-way ANOVA with Bonferroni\'s multiple comparison test, using the GraphPad Prism 6.0 software. Differences were considered statistically significant if *P* \< 0.05.

Results and discussion {#s3}
======================

We set up a series of hydroponic cultures with each group receiving different doses of kifunensine during the period following agro-infiltration to harvest (Figure [1A](#F1){ref-type="fig"}). For transient overexpression of gCTB in *N. benthamiana*, the magnICON tobamovirus replicon vector was employed, which was delivered via vacuum-mediated agroinfiltration (Hamorsky et al., [@B19]). Then plants were transferred from soil to water and treated with varying doses of kifunensine (Figure [1A](#F1){ref-type="fig"}). Water in the hydroponic cultures was changed every other day along with a fresh dose of kifunensine based on the treatment regimen (Figure [1B](#F1){ref-type="fig"}). Groups of plants were treated without (termed 0 kif) or with kifunensine either once, twice or thrice (termed 1 kif, 2 kif, and 3 kif, respectively). Kifunensine-treated groups received 5 μM at a time except the 3 kif group, which received 2.5 μM prior to the day of harvest (Figure [1B](#F1){ref-type="fig"}). To examine the effect of kifunensine treatment on *N*-glycan profiles of gCTB, the purified protein from different kifunensine treatment groups (gCTB~Kif~) was subjected to Endo H and PNGase F digestions. Endo H is a glycosidase which cleaves within the chitobiose core of high mannose and some hybrid oligosaccharides from *N*-linked glycoproteins. PNGase F, on the other hand, cleaves mammalian *N*-glycans (including HMGs) between the innermost *N*-acetylglucosamine (GlcNAc) and Asn residues but fails to cleave those containing α(1, 3)-linked fucose, which are mostly found in plant and some insect glycoproteins (Wilson et al., [@B66]; Bardor et al., [@B3]). Western blot analysis probed with a goat anti-CTB antiserum showed two distinct bands for gCTB without any glycosidase treatment (Figure [2A](#F2){ref-type="fig"} and Supplementary Figure [1](#SM1){ref-type="supplementary-material"}, Uncut lanes). This is due to incomplete *N*-glycan occupancy at Asn4 of the protein; the upper band corresponds to glycosylated gCTB and the lower band indicates the aglycosylated form (Hamorsky et al., [@B19]). Despite that gCTB contained a KDEL C-terminal ER retention signal, the protein was recalcitrant to Endo H and PNGase F digestion (Figure [2A](#F2){ref-type="fig"}, 0 Kif lanes). This indicates that gCTB was not retained in the ER effectively and thus modified with complex and plant-specific glycoforms in the Golgi. Conversely, the results revealed the limitation of the KDEL tag-based ER-retention strategy to enrich HMGs on this protein. By contrast, the 2 kif condition appeared to be sufficient to modify the glycan composition of gCTB to a HMG-rich profile, because gCTB\'s glycans were almost entirely cleaved by Endo H and PNGase F in the 2 kif and 3 kif groups but not in the 0 and 1 kif groups (Figures [2A,B](#F2){ref-type="fig"}). Additionally, gCTB was no longer detectable by anti-fucose and anti-xylose antibodies after two rounds of kifunensine treatments, indicating that the levels of plant-specific glycans containing α(1, 3)-linked fucose and β(1, 2)-linked xylose moieties were significantly reduced compared to single and no-kifunensine treated conditions (Figure [2C](#F2){ref-type="fig"}). Thus, these results demonstrate that hydroponic kifunensine treatment of *N. benthamiana* is effective at reducing plant-specific glycoforms while increasing HMGs in gCTB\'s glycan profile under transient overexpression conditions.

![Endoglycosidase digestion of gCTB. **(A)** A representative immunoblot showing gCTB treated with a mock control (uncut), Endo H or PNGase F upon 0, 1, 2, and 3 kif treatments. **(B)** Densitometric analyses to calculate the fraction of glycosylated band resistant to either of the enzymes. Band intensity was normalized by calculating the fraction of residual undigested glycosylated gCTB band remaining after overnight digestion with respective glycosidases over glycosylated band intensity of an undigested gCTB sample, both receiving similar doses of kifunensine treatment. **(C)** A representative immunoblot showing gCTB from 0, 1, 2, and 3 kif conditions probed with α-fucose and β-xylose antibodies. **(D)** The quantification of gCTB~kif~ in *N. benthamiana* using GM1-ELISA from clarified extracts. Statistical significance was analyzed by one-way ANOVA followed by Bonferroni\'s multiple comparison tests \[^\*^*P* \< 0.05; ns, not significant (*P* \> 0.05)\].](fpls-09-00062-g0002){#F2}

To test the impact of kifunensine treatment on gCTB accumulation, clarified leaf extracts were analyzed by GM1-ELISA. Results indicated that the gCTB yield was affected by kifunensine treatment; 2- and 3-kif conditions decreased the yield by \~30 and 75%, respectively (Figure [2D](#F2){ref-type="fig"}). To understand the mechanism for the reduction of gCTB accumulation under kifunensine treatment, we measured transcript levels of ER stress-related genes; previous studies showed that the modification of glycan structure might cause ER stress, which was associated with the reduction of a translation rate (Schneider et al., [@B52]; Lageix et al., [@B26]). ER stress induces the unfolded protein response (UPR). Basic-region leucine zipper 60 (bZIP60) is a transcription factor involved in a major arm of UPR in plants, which activates the expression of ER-resident molecular chaperons (Iwata and Koizumi, [@B21]; Hamorsky et al., [@B19]). Thus, we analyzed the expression of bZIP60 and two representative ER chaperons, luminal binding protein (BiP) and protein disulfide isomerase (PDI). Two days post vector inoculation under 5 mM kinfunesine supplemented conditions, we found that the expression levels of *BiP, PDI*, and *bZIP60* significantly increased by 7.0, 3.5, and 3.2 fold, respectively, compared with those of non-treated plants (Figures [3A--C](#F3){ref-type="fig"}). Collectively, these results suggest that kifunensine treatment induced strong ER stress, which in turn led to the reduction of gCTB expression levels. It is known that ER stress gives rise to reactive oxygen species (ROS), which causes the reduction of a translation rate mediated with the protein kinase GCN2 (Lageix et al., [@B26]; Liu et al., [@B32]). Based on this mechanism, we hypothesized that ascorbic acid might block ROS signaling and subsequent reduction of gCTB expression in kifunensine-treated *N. benthamiana*. To test this hypothesis, plants were incubated for 2 days under the co-treatments with 0.3 mM of ascorbic acid and 5 mM of kifunensine. As shown in Figures [3A--B](#F3){ref-type="fig"}, the ascorbic acid co-treatment significantly suppressed the kifunensine-induced elevation of *BiP, PDI*, and *bZIP60* transcript levels by \~50%, although they were still 2.9, 2.0, and 2.2-fold higher, respectively, than those of no-kifunensine conditions. Consistent with this, the reduction of gCTB yield associated with kifunensine treatment was significantly recovered by ascorbic acid co-treatment (though still \~35% lower than non-kifunensine treatment conditions) at 5 days post vector inoculation (Figure [3D](#F3){ref-type="fig"}). Meanwhile, ascorbic acid alone did not induce a significant change in ER stress marker gene expression or gCTB accumulation levels (Figures [3A--C](#F3){ref-type="fig"}). Higher doses of ascorbic acid were not effective at improving gCTB yield any further (data not shown). To further dissect the ER stress response, we analyzed the ER stress marker genes in plants that were infiltrated with an empty vector and treated under the same hydroponic conditions. The results were overall similar to those of gCTB-expressing plants; kifunensine treatment increased *BiP, PDI*, and *bZIP60* levels by 2--3 folds, while co-treatment with kifunensine and ascorbic acid did not show such effects (Figures [3E--G](#F3){ref-type="fig"}). Thus, it seems that kifunensine treatment alone induces significant ER stress in plants, at least under the hydroponic conditions employed here, although overexpression of recombinant proteins could exacerbate the stress further. Taken together, these results demonstrate that, although hydroponic kifunensine treatment of *N. benthamiana* causes ER stress and thereby reduces gCTB yields upon transient over-expression, ascorbic acid co-treatment can mitigate the adverse effect and recover the recombinant protein expression levels.

![qRT-PCR analysis of ER stress related genes. **(A--C)** Total leaf RNA was isolated at 2 days post vector inoculation under no kifunensine treatment (Non), no kifunensine treatment with 0.3 mM ascorbic acids (Non + AA), 5 mM kinfunensine treatment (3 Kif) or under 5 mM kifunensine plus 0.3 mM ascorbic acids (3 Kif + AA). All groups have undergone the same procedural manipulations except for Kif or AA treatments. The expression levels of *BiP* **(A)**, *PDI* **(B)**, and *bZIP60* **(C)** were quantified by qRT-PCR. The 18S rRNA was used for the normalization of cDNA amount. Values indicated as fold increase to the average normalized value for the Non group and are expressed as means ± SEM of biological replicates (*n* = 9). **(D)** Quantification of gCTB from Non, Non + AA, 3 kif and 3 kif + AA conditions in *N. benthamiana* leaf extract using GM1-ELISA (*n* = 9). **(E--G)** qRT-PCR analysis of *BiP* **(E)**, *PDI* **(F)**, and *bZIP60* **(G)** of empty vector-inoculated plants. Plants were treated the same way as above, excluding the Non + AA conditions. Values indicated as fold increase to the average normalized value for the Non group and are expressed as means ± SEM of biological replicates (*n* = 9). Statistical significance was analyzed by one-way ANOVA followed by Bonferroni\'s multiple comparison tests \[^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01; ^\*\*\*^*P* \< 0.001; ns, not significant (*P* \> 0.05)\].](fpls-09-00062-g0003){#F3}

Next, we evaluated the impact of *N. benthamiana* kifunensine treatment on the *N*-glycans of recombinant HIV-1 gp120. As gp120 is one of the most heavily *N*-glycosylated viral proteins known so far (Kwong et al., [@B25]; Zhou et al., [@B69]), the protein provides an extreme case example to demonstrate the effectiveness of the present method. Additionally, it has been shown that the *N*-glycans of gp120 on primary HIV-1 isolates are predominantly HMGs (Doores et al., [@B10]; Bonomelli et al., [@B5]). Thus, the development of a high-mannose-rich recombinant gp120 is deemed important for an effective HIV vaccine. Since gp120 has a large number (15--25) of *N*-glycans (Kwong et al., [@B25]; Zhou et al., [@B69]), we employed 3 kif conditions described above (see Figure [1B](#F1){ref-type="fig"}). The recombinant HIV-1 gp120 from the clade C strain DU156 was expressed using the magnICON vector. As observed in gCTB expression (Figure [3](#F3){ref-type="fig"}), gp120-expressing plants showed a significant increase in ER stress marker gene expression under kifunensine treatment conditions, but the stress response could be blunted by ascorbic acid co-treatment (Supplementary Figure [2](#SM1){ref-type="supplementary-material"}). The plant-produced gp120 was purified using a 3-step purification procedure including immobilized metal affinity chromatography followed by *Galanthus nivalis* lectin and a final diethylaminoethyl (DEAE)-based ion-exchange chromatography. The lectins of *G. nivalis* bind to D-mannose and have been used for the purification of HIV gp120 (Srivastava et al., [@B55]; Martin et al., [@B36]). In SDS-PAGE analysis, the plant-expressed gp120 showed a noticeably smaller molecular weight (\~75 kDa) than human embryonic kidney (HEK293T) cell-produced gp120 (\~120 kDa) (Supplementary Figure [3A](#SM1){ref-type="supplementary-material"}). This could be due to differences in their glycosylation patterns, including compositions and occupancy; the theoretical molecular size of the plant-expressed gp120 without glycans is 52.9 kDa based on its amino acid composition. Glycans account for approximately half of the molecular mass of gp120 (Behrens and Crispin, [@B4]; Ward and Wilson, [@B64]). Thus, some, if not most, of the potential *N*-glycosylation sites may not have been glycosylated in plants. Nevertheless, the plant-made gp120 showed a similar binding curve to that of the mammalian cell-produced counterpart in a sandwich ELISA using the broadly neutralizing, anti-CD4 binding site monoclonal antibody VRC01 (Wu et al., [@B67]; Hamorsky et al., [@B17]) and an anti-gp120 antiserum, suggesting that the plant-produced protein, overall, retains antigenic integrity of gp120 (Supplementary Figure [3B](#SM1){ref-type="supplementary-material"}). To dissect the glycan profile of gp120, a combination of comparative high-performance liquid chromatography (HPLC) and mass spectrometry (MS) was carried out. Results indicated that gp120 from HEK293T cells contained a mixture of terminal mannose (39.4%) and/or β(1, 4)-galactose-linked (18.4%), GlcNAc (9.6%) and α(1, 6)-linked fucose (32.6%) as complex glycans. In contrast, gp120-HDEL produced in *N. benthamiana* without kifunensine treatment showed increased HMG content (91%) (Man~5−9~GlcNAc~2~) (Figure [4](#F4){ref-type="fig"} and Table [1](#T1){ref-type="table"}), signifying that the protein was retained in the ER, although there was a small percentage of complex glycans, including GlcNAc-linked and plant-specific β(1, 2)-xylose glycoforms. Thus, it is evident that a minor fraction of gp120-HDEL escaped from the ER into the Golgi apparatus. This in turn highlights the limitation of the H/KDEL signal-based ER-retention strategy to restrict glycosylation heterogeneity, as we have previously shown with gCTB-KDEL (Matoba, [@B40]). A previous study by Rosenberg et al. showed that the glycan composition of a plant-produced gp140-KDEL had a similar HMG-rich profile, but with no detectable plant-specific glycoforms (Rosenberg et al., [@B49]). However, this could be due to differences in expression vector/conditions, the envelope glycoproteins used (C clade Du156 gp120 in the present study vs. SHIV-89.6P gp140 in Rosenberg et al.), and/or the methods used for glycan analysis. Meanwhile, for plants treated with kifunensine, the HIV envelope protein showed a distinct HMG-rich glycan profile with a high percentage of Man9 (64.5%), which was much higher than that (20.3%) of the protein produced without kifunensine treatment (Figure [4](#F4){ref-type="fig"} and Table [1](#T1){ref-type="table"}). Interestingly, there was a small percentage of α(1, 3)-linked glucose structure (11.3%), which may represent incompletely folded or misfolded gp120 (Dejgaard et al., [@B9]). This might partly explain ER stress and the reduction of production yield upon kifunensine treatment. Since kifunensine is an α-mannosidase I inhibitor that blocks the processing of Man9 HMGs to other glycoforms, the significantly high content of Man9 structure indicates the effectiveness (albeit not perfect) of the present kifunensine treatment conditions for the transient overexpression of Man9-rich glycoproteins in whole plants. In this study, we did not examine the vaccine efficacy of the Man9-rich gp120 expressed under kifunensine-treated conditions, because monomeric gp120 is ineffective at inducing HIV-neutralizing antibodies. Development of a stable and soluble trimeric gp120 vaccine antigen inducing broadly neutralizing antibodies remains to be a major challenge in HIV vaccine research (Karlsson Hedestam et al., [@B23]; Ward and Wilson, [@B64]). Nevertheless, the results presented herein provide a basis to perform such a study using trimeric gp120, when it becomes available, as Man9-rich HMG glycans may mimic the glycosylation profile of the natural envelope glycoprotein on HIV virions while enhancing vaccine efficacy via increased affinity to C-type lectin receptors (Doores et al., [@B10]; Eggink et al., [@B11]; Bonomelli et al., [@B5]).

![*N*-linked glycan profile of HIV-1 gp120. Chromatogram showing MS analyses of RP-HPLC separated pyridylamino (PA)-labeled glycans isolated from different growth conditions along with sugar legends (HEK: HEK 293T cell line; gp120-HDEL: plant-produced recombinant gp120-HDEL).](fpls-09-00062-g0004){#F4}

###### 

Relative *N*-glycan composition of gp120 expressed in different growth conditions: HEK produced gp120, *Nicotiana benthamiana* produced gp120-HDEL and *Nicotiana benthamiana produced* gp120-HDEL + 3 Kif.

  **Structure**                   **Ratio (%)**                 
  ------------------------------- --------------- ------ ------ ------
  Mannose-type structure          M3              0.5    --     --
                                  M4              1.1    1.8    --
                                  M5              9.2    4.2    1.1
                                  M6B             4.6    7.2    8.9
                                  M7A             4.5    5.0    1.2
                                  M7B             1.0    11.9   1.8
                                  M8A             10.3   41.1   9.8
                                  M8B             0.9    --     1.4
                                  M9              7.3    20.3   64.5
  Glc-linked structure            GlcM6           --     1.0    7.8
                                  GlcM7           --     --     3.5
  GlcNAc-linked structure         ^GN^M3          --     4.7    --
                                  ~GN~M3          3.2    --     --
                                  GN2M3           4.9    --     --
                                  GNM5            0.9    --     --
                                  GN3M3           0.6    --     --
  β 1,2-Xyl-linked structure      GNM3X           --     2.8    --
  α 1,6-Fuc-linked structure      ^GN^M3F         4.4    --     --
                                  ~GN~M3F         1.3    --     --
                                  GN2M3F          18.0   --     --
                                  GN3M3F          7.0    --     --
                                  GN4M3F          1.9    --     --
  β 1,4-Gal-linked structure      GalGN2M3        2.1    --     --
                                  GalGN2M3F       9.8    --     --
                                  GalGN3M3F       2.8    --     --
                                  GalGNM5         0.6    --     --
                                  Gal2GN2M3F      3.1    --     --
  Total Mannose-type structure                    39.4   91.5   88.7
  Total GlcNAc-linked structure                   9.6    4.7    --
  Total Fuc-linked structure                      32.6   --     --
  Total Gal-linked structure                      18.4   --     --

To conclude, we have shown that the hydroponic treatment of *N. benthamiana* with kifunensine allows us to obtain Man9-rich HMG-displaying recombinant glycoproteins upon transient overexpression. Our findings warrant further studies evaluating the effectiveness of kifunensine treatment for other glycoproteins, particularly those without a H/KDEL tag, optimization of hydroponic culture conditions, and feasibility of this approach for large-scale production. With additional investigations for glycosylation and bioprocess optimizations, our strategy discussed here opens up new possibilities of producing mannosylated recombinant vaccine antigens that can be efficiently targeted to C-type lectin receptors. Identification and characterization of *N. benthamiana* mannosidase(s) targeted by kifunensine may aid in understanding the glycosylation regulation in plants and developing glyco-engineered host plants for vaccine production.
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